Hollywood, June 29, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCPINK: ETST), an innovative biotech company focused on cannabis CBD-based (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, medical devices receives coverage initiation from SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, with a price target of $4.12.
“We are honored to be covered by a well-respected Wallstreet equity firm, which took notice on our emerging trusted brand, Earth Science Tech, Inc. (OTC: ETST). Our team is passionate and truly believes in our brand. We truly believe ETST will emerge as a leading biotech, and most importantly, we plan to keep helping individuals to positively change and improve their lives.” Stated, Nickolas S. Tabraue, ETST’s President and COO. View full report: ( here ) Report Highlights :
- Large Market Opportunity CBD pharmaceuticals and nutraceuticals is one of the fasted growing sectors in the legal cannabis industry. Clinical research studies have demonstrated that CBD nutraceuticals have the potential to treat arthritis, MS, chronic pain, PTSD, depression, epilepsy and a myriad of other illnesses and disorders. The North American legal cannabis market stood at ~$7 billion in 2016, with strong growth prospects. The market is expected to reach ~$22 billion by 2020, representing a CAGR of 25%. Eight states in the US have legalized the use of recreational marijuana (cannabis), while 29 states allow marijuana to be used for medicinal purpose. We believe favorable regulatory environment will provide further tailwind to ETST. However, recent stance by DEA that it considers CBD as a Schedule 1 substance has created some overhang.
- Strong Product Pipeline to Fuel Growth The product pipeline remains robust with series of CBD based nutraceutical, supplements as well pharmaceutical products anticipated to be launched in 2017 and early 2018. The pipeline comprises three sports supplements to be launched in 2017, two CBD based pharmaceuticals drugs to be launched in 1Q/2Q18, new e-liquid and edible gummies from it’s newly form subsidiary to be launched 3Q/2017, and three patent pending CBD based nutraceuticals to be launched by the end of the calendar year 2017.
- New Product Launches to Provide Fillip to Revenues The recent launch of new flavored CBD oil ( Orange Blossom ), organic chocolate CBD line , and pet CBD is expected to boost revenues this year. The initial sales of organic chocolates developed in partnership with Karmavore Superfood have been selling rapidly with great excitement and feedback from store owners and customers. The sample test studies conducted by ETST point to Orange Blossom being the best tasting CBD oil available, and the company foresee it being a huge hit.
- New Strategic Partnerships and Aggressive Marketing Push to Yield Strong Order Flow The strategic partnerships with Karmavore Superfood , Forzagen, and Smart Medicines will help ETST to diversify product offerings and accelerate entry in new markets. ETST is aggressively spending on marketing via presence in high profile magazines ( Natural Awakenings ), web portals (MassRoots), and one of the tow only CBD companies recommended by the Institute of Natural Healing (INH) for cancer. We believe these initiatives will help ETST reach more users, gain major brand recognition, and build early demand for its innovative new products.
- Initiate Coverage with a Price Target of $4.12 We see ETST as a high risk and high reward play on the burgeoning legal cannabis and hemp industry, targeting the fastest growing sub segment (hemp derived CBD). The target of $4.12 assumes that the company is successful in executing its growth strategy revolving around new product launches, strategic partnerships and aggressive marketing campaigns. Key risk include any adverse regulatory stance that could materially damage company growth prospects.
SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The full report will also be available on the ETST's website under Investors . About Earth Science Tech, Inc. (ETST): Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world's best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. T
To learn more please visit: www.earthsciencetech.com ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products. View ETST's accomplishments and reports on its High-Grade CBD Hemp Oil: ( here ) About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.
To learn more please visit: www.Earthsciencepharmaceutical.com The accuracy of the MSN-2 medical device for the diagnosis of women with Chlamydia has already been proven via a study of 510 female patients, which showed PCR testing results on paired samples to be identical for 493 (96.6%) of the 510 women. To view this study, visit Evaluation of a Modified Sanitary Napkin as a Sample Self-Collection Device for the Detection of Genital Chlamydial Infection in Women . About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide.
To learn more please visit: www.Cannabisthera.com Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Cannabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. The THREE (3) cannabis cannabinoid-based nutraceutical patents and TWO (2) generic pharmaceutical drugs will be based on ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015.
About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by it's unique Kanna and CBD formula. Kanna and CBD synergistically enahnce one another, providing optimal relaxation, an uplifiting sensation, enahnce focus, and help with nicotine addiction based on their propeties.
Website coming soon: www.kannabidioidinc.com
About SeeThruEquity: Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion. SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City. For more information visit www.seethruequity.com FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products. SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Dave Demarest (305)-546-7640 Earth Science Tech, Inc. Nickolas S. Tabraue, P/D/COO (305)-615-2118
